Amyotrophic lateral sclerosis (ALS) affects the nerve cells in the brain and spinal cord that control muscle movement. Different types of ALS cause symptoms to begin in a certain part of the body and ...

Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...

Musculoskeletal (MSK) disorders affect the muscles, bones, joints, and tissues. In children, they may be due to infection, cancer, inflammatory arthritis, or progressive muscle disorders. MSK ...

Base Editing (BE) and Prime Editing (PE), novel precision tools of the CRISPR/Cas toolbox, have emerged as transformative technologies that enable highly specific genetic modifications. Their ...

In a finding that opens the door to the development of targeted therapies for various muscle disorders, newly published research identifies key mechanisms of skeletal muscle regeneration and growth of ...

Temporomandibular disorders (TMDs) is a broad term encompassing structural abnormalities, disabilities, or pain affecting the temporomandibular joint (TMJ) and related muscular and bony components.

Recent research from the University of Houston College of Pharmacy identifies key mechanisms of skeletal muscle regeneration and growth of muscles following resistance exercise. It's a finding that ...

Dermatomyositis is an inflammatory disease that can cause muscle pain and weakness. While it can be fatal, deaths are considered rare when the condition is diagnosed and treated early. Dermatomyositis ...

Belonging to the same group of autoimmune diseases, both dermatomyositis and polymyositis cause muscle inflammation and weakness. But dermatomyositis also affects your skin and is more likely to ...

For people living with advanced liver disease, the illness affects much more than the liver itself. One of the most serious complications is the gradual loss of muscle mass and strength, a condition ...

June 11 (Reuters) - Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a ...